Following a stellar 2QFY2021 performance, analysts have maintained their “buy” or “add” calls on UG Healthcare, but some have lowered their target prices. 

CGS-CIMB’s Ong Kang Chuen maintained his $1.70 target price on the stock, expecting “stronger quarters ahead” due to a further rise in average selling prices (ASP) of rubber gloves. 

UGHC recorded a 2QFY2021 net profit of $32.3 million, 42% higher q-o-q and a jump of 58 times y-o-y. This was ahead of his expectations, which had forecast a $30m net profit for the quarter. 

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook